The contribution of the individual blood elements to the variability of thromboelastographic measures

Noorman, Femke; Hess, John R.

doi:10.1111/trf.14884

Cited by 22 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… observed shorter initiation times in case plasma was used when WB samples were diluted to 50%. Also, faster propagation rates and higher clot strength were obtained when plasma was used, which was recently confirmed by Noorman and Hess for a range of PLT concentrations. The other authors report corresponding enhanced coagulation or attenuated fibrinolysis when plasma was used as diluent instead of colloids .…”

Section: Techniques and Methodssupporting

confidence: 71%

“…The thromboelastographic reaction is contributed to by platelets and clotting factors, and in order to determine the contribution of fibrinogen to clot strength, reaction mixtures with inhibitors of PLT glycoprotein IIb/IIIa (such as abciximab) or PLT actin polymerization (such as cytochalasin D; FIBTEM test) are available. Of note, the contribution of PLTs to clot strength is not completely eliminated by these inhibitors, so, it is not recommended to substitute the Clauss method to determine fibrinogen concentration by a thromboelastographic‐based method . Coagulation may also be started by activating PLTs with arachidonic acid (which is converted into thromboxane A 2 for stimulation of the thromboxane receptor) , ADP (P 2 Y 12 receptors) , collagen (glycoproteins Ia and VI) or convulxin (glycoprotein VI) .…”

Section: Techniques and Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Thromboelastography as a tool to evaluate blood of healthy volunteers and blood component quality: a review

2019

View full text Add to dashboard Cite

Thromboelastography is a technique to evaluate the overall coagulation behaviour of blood and blood components. First, we evaluated the literature concerning the use of thromboelastography for characterizing coagulation behaviour of healthy volunteers, such as blood donors. Overall coagulation is sensitive to gender, most likely caused by the difference in haematocrit and plasma content of male versus female blood. Smaller and less pronounced effects in thromboelastographic response are caused by differences in fibrinogen level or by use of oral contraceptives. Short‐term hypercoagulable effects are observed after smoking or blood donation, while small effects of non‐steroidal anti‐inflammatory drugs on platelets are also present. Second, in whole blood donations, the thromboelastographic variables are also sensitive to storage time and temperature, but are less sensitive to levels of clotting factors. Platelet count and quality have little influence on thromboelastographic variables, and differences are mainly observed at counts <100x109/l, after extended storage time of platelet concentrates or storage under specific conditions, including freezing. Thromboelastographic profiles of plasma samples are mainly affected by residual cell counts, microparticles and fibrinogen levels, and less by levels of clotting factors. Taken together, publications have shown that as an overall clotting test, thromboelastography may support optimization of blood component preparation and storage with regard to temperature, time and secondary and tertiary treatments. Minimal deviations of in vitro quality are most reliable demonstrated when an appropriate assay is chosen.

show abstract

Section: Techniques and Methodssupporting

confidence: 71%

Section: Techniques and Methodsmentioning

confidence: 99%

Thromboelastography as a tool to evaluate blood of healthy volunteers and blood component quality: a review

2019

View full text Add to dashboard Cite

show abstract

“…A decreased MA is indicative of low clot strength, which could be due to decreased platelet contribution or decreased fibrinogen, whereas an increased MA is indicative of high clot strength, which could be due to increased platelet contribution. 8,10,12,13,18,21,25,27 Citrated Functional Fibrinogen (CFF)…”

Section: Crt Mamentioning

confidence: 99%

“…In conjunction with CRT, this assay enables the contributions of fibrin and platelets to clot strength to be determined. 7,10,12,14,15,22,25,27 Method Comparison A method comparison study was conducted at 12 US clinical sites collecting patient samples following CLSI EP09-A3 Guidelines. Enrolled were adult patients (male or females 18 years of age and older) who met the full or limited trauma team criteria of the American College of Surgeons or similar criteria established per institutional guidelines.…”

Section: Cff Mamentioning

confidence: 99%

A comparison between the TEG 6s and TEG 5000 analyzers to assess coagulation in trauma patients

Neal

Moore

Walsh

et al. 2019

J Trauma Acute Care Surg

View full text Add to dashboard Cite

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

show abstract

“…Noorman and Hess's statements in a recent in vitro study highlight the divergent utility of the Thrombelastograph (TEG™, Haemonetics, Braintree, MA) between pathologists and clinicians managing coagulopathic, bleeding patients. The principle of visco‐elastic tests such as the TEG™ are the global nature of whole blood (WB) evaluation so artificial separation in this study of stored, frozen blood into discrete individual components, which are then mixed in various ratios, holds very little clinical applicability.…”

mentioning

confidence: 99%

Use of Thrombelastography as a global monitor of hemostasis

Pivalizza

2019

Transfusion

View full text Add to dashboard Cite

The contribution of the individual blood elements to the variability of thromboelastographic measures

Cited by 22 publications

References 20 publications

Thromboelastography as a tool to evaluate blood of healthy volunteers and blood component quality: a review

Thromboelastography as a tool to evaluate blood of healthy volunteers and blood component quality: a review

A comparison between the TEG 6s and TEG 5000 analyzers to assess coagulation in trauma patients

Use of Thrombelastography as a global monitor of hemostasis

Contact Info

Product

Resources

About